Clarivate™ has revealed the annual list of Highly Cited Researchers™ 2024, curated by its experts at the Institute for Scientific Information™ (ISI). Since 2001, Clarivate has identified the small fraction of international research scientists and social scientists who have demonstrated significant and broad influence in their respective field(s) of research.
Drawing on data from the Web of Science™, together with qualitative analysis performed by experts at the ISI at Clarivate, a new list is determined each year. Each researcher selected has authored multiple Highly Cited Papers™ which rank in the top 1% by citations for their field(s) and publication year in the Web of Science™ over the past decade.
This year, 6,886 Highly Cited Researcher designations have been awarded to 6,636 individual researchers from institutions in 59 countries and regions, who have made outstanding contributions to extending the frontiers of knowledge and advancing innovations that make the world healthier, more sustainable and drive societal impact.
For the ninth consecutive year, Josep Tabernero has been selected for pushing the boundaries of cancer research and therapy under the category of Clinical Medicine that includes a total of 443 named leaders this year. Joining Josep in this same category is VHIO’s Enriqueta Felip, who has now been listed for a seventh year running, and Ana Oaknin.
“I am truly honored to have been included in this year’s listing of Highly Cited Researchers. Importantly, this recognition is not about individual efforts or achievements. Rather, it is the result of team science and strong collaboration. I am privileged to work alongside so many other dedicated colleagues and hugely talented researchers nationally and globally,” said Josep Tabernero, VHIO’s Director and Head of the Medical Oncology Department at the Vall d’Hebron University Hospital (HUVH) in Barcelona.
“I echo Josep’s words and take this opportunity to also acknowledge the extraordinary efforts of our translational teams and talents, research partners, and other specialties in accelerating cancer research and harnessing those discoveries to drive progress against cancer,” added Enriqueta Felip, Head of VHIO’s Thoracic Tumors Group and Vall d’Hebron’s Thoracic Cancer Unit.
“Collaboration is the key to advancing cancer science and medicine. This designation also reflects the tremendous work of healthcare teams and professionals in oncology who work together to improve outcomes for cancer patients and reduce the devastating burden of this disease,” said Ana Oaknin, Head of VHIO’s Gynecological Malignancies Group and the Gynecological Tumors Unit at HUVH.
On behalf of all at VHIO, we congratulate Josep, Enriqueta and Ana for this important recognition and applaud their important and impactful contributions to cancer research and clinical oncology.
To access the Clarivate list of Highly Cited Researchers 2024 please click here.
